tirzepatide vs semaglutide weight loss efficacy side effects Cardiovascular outcomes of and for patients with type 2 diabetes in clinical practice Tirzepatide vs Semaglutide: A Comprehensive

The 2021 STEP 4 trial, published in JAMA, showed that people who continued semaglutide after an initial 20-week run-in kept losing weight, while those who switched to placebo regained nearly 7% of their body weight, confirming that ongoing treatment is key to maintaining results

Larger, well-designed studies are needed

Wegovy and Ozempic are virtually identical, both using semaglutide as their primary ingredient, but are Wegovy is only prescribed for weight loss and Ozempic is only prescribed for type 2 diabetes management

Autophagy during viral infection - a double-edged sword

A strong workflow assigns ownership, due dates, and follow-up rules

Epub 1995/08/01